Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 1
1999 1
2001 2
2002 3
2003 7
2004 8
2005 4
2006 9
2007 9
2008 16
2009 18
2010 17
2011 22
2012 17
2013 20
2014 14
2015 13
2016 7
2017 8
2018 8
2019 7
2020 5
2021 1
2022 1
2024 6
2025 7
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

206 results

Results by year

Filters applied: . Clear all
Page 1
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group. Julius S, et al. Lancet. 2004 Jun 19;363(9426):2022-31. doi: 10.1016/S0140-6736(04)16451-9. Lancet. 2004. PMID: 15207952 Clinical Trial.
BACKGROUND: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test the hypothesis that for the same blood-pressure control, valsartan would reduce cardiac morbidity and mortality more than amlodipine in hypertensive patient …
BACKGROUND: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test the hypothesis that for the sa …
Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study.
Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, Guo W. Williams B, et al. Hypertension. 2017 Mar;69(3):411-420. doi: 10.1161/HYPERTENSIONAHA.116.08556. Epub 2017 Jan 16. Hypertension. 2017. PMID: 28093466 Clinical Trial.
Patients (n=454; mean age, 67.7 years; mean seated systolic blood pressure, 158.6 mm Hg; mean seated pulse pressure, 69.7 mm Hg) were randomized to receive once-daily sacubitril/valsartan 200 mg or olmesartan 20 mg, force titrated to double the initial doses after 4 weeks, …
Patients (n=454; mean age, 67.7 years; mean seated systolic blood pressure, 158.6 mm Hg; mean seated pulse pressure, 69.7 mm Hg) were random …
Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open-Label, Noninferiority Study (PARASOL Study).
Yamamoto K, Yarimizu D, Shimanishi A, Eguchi S, Iekushi K, Takami Y, Nozato Y, Kario K, Rakugi H. Yamamoto K, et al. J Clin Hypertens (Greenwich). 2025 Jan;27(1):e14938. doi: 10.1111/jch.14938. Epub 2024 Dec 4. J Clin Hypertens (Greenwich). 2025. PMID: 39632589 Free PMC article. Clinical Trial.
In this open-label, multicenter study, we aimed to demonstrate the efficacy and safety of sacubitril/valsartan versus amlodipine, one of the most widely used CCBs, after 8 weeks of treatment. ...Sacubitril/valsartan, a potent antihypertensive drug comparable …
In this open-label, multicenter study, we aimed to demonstrate the efficacy and safety of sacubitril/valsartan versus amlodipine …
Effects of valsartan vs amlodipine and achieved lower blood pressure on the incidence of end-stage kidney disease: The VALUE Trial.
Olsen E, Jamerson K, Schmieder RE, Søraas CL, Mariampillai JE, Mancia G, Kjeldsen SE, Heimark S, Mehlum MH, Liestøl K, Larstorp ACK, Halvorsen LV, Høieggen A, Burnier M, Rostrup M, Julius S, Weber MA. Olsen E, et al. Eur J Intern Med. 2025 Mar;133:55-63. doi: 10.1016/j.ejim.2024.12.021. Epub 2024 Dec 18. Eur J Intern Med. 2025. PMID: 39694747 Free article. Clinical Trial.
The primary outcome, a composite of cardiac morbidity and mortality, was neutral between valsartan and amlodipine. On valsartan 47 patients (0.61 %) and on amlodipine 50 patients (0.66 %) developed ESKD (HR=1.02, 95 % CI 0.68-1.52, p =0.94). ...CONCLUS …
The primary outcome, a composite of cardiac morbidity and mortality, was neutral between valsartan and amlodipine. On valsa …
Randomized-controlled trial of sacubitril/valsartan and amlodipine combination in Japanese uncontrolled hypertensive patients (J-SAMIT).
Kario K, Rakugi H, Ito C, Sayyed S, Kitamura T, Tanaka Y, Malhotra A. Kario K, et al. Hypertens Res. 2026 Sep;49(9):2587-2600. doi: 10.1038/s41440-026-02704-7. Epub 2026 Jun 30. Hypertens Res. 2026. PMID: 42373836 Free PMC article. Clinical Trial.
This multicenter, randomized, double-blind, parallel-group, active-controlled study aimed to demonstrate a superior BP-lowering effect of sacubitril/valsartan (SacVal) and amlodipine (AML) combination therapy vs SacVal monotherapy in Japanese patients with grade / …
This multicenter, randomized, double-blind, parallel-group, active-controlled study aimed to demonstrate a superior BP-lowering effect of sa …
Additivity of nebivolol/valsartan single-pill combinations versus other single-pill combinations for hypertension.
Ishak J, Rael M, Punzi H, Gradman A, Anderson LM, Patel M, Ali S, Ferguson W, Neutel J. Ishak J, et al. J Clin Hypertens (Greenwich). 2018 Jan;20(1):143-149. doi: 10.1111/jch.13132. Epub 2017 Nov 5. J Clin Hypertens (Greenwich). 2018. PMID: 29105958 Free PMC article. Clinical Trial.
Additive effects of four nebivolol/valsartan SPC doses (5 mg/80 mg, 5/160 mg, 10/160 mg, 10/320 mg nebivolol/valsartan) were compared with five Food and Drug Administration-approved non-beta-blocker/renin-angiotensin-aldosterone system inhibitor SPCs (aliskiren/hydr …
Additive effects of four nebivolol/valsartan SPC doses (5 mg/80 mg, 5/160 mg, 10/160 mg, 10/320 mg nebivolol/valsartan) were c …
Valsartan Amlodipine Randomized Trial (VART): design, methods, and preliminary results.
Nakayama K, Kuwabara Y, Daimon M, Shindo S, Fujita M, Narumi H, Mizuma H, Komuro I. Nakayama K, et al. Hypertens Res. 2008 Jan;31(1):21-8. doi: 10.1291/hypres.31.21. Hypertens Res. 2008. PMID: 18360014 Clinical Trial.
Antihypertensive therapy has been well established to reduce hypertension related morbidity and mortality, but the optimal therapy for Japanese patients remains unknown. The Valsartan Amlodipine Randomized Trial (VART), a prospective randomized open-label trial, was …
Antihypertensive therapy has been well established to reduce hypertension related morbidity and mortality, but the optimal therapy for Japan …
Valsartan decreases platelet activity and arterial thrombotic events in elderly patients with hypertension.
Wu F, Wang HY, Cai F, Wang LJ, Zhang FR, Chen XN, Yang Q, Jiang MH, Wang XF, Shen WF. Wu F, et al. Chin Med J (Engl). 2015 Jan 20;128(2):153-8. doi: 10.4103/0366-6999.149185. Chin Med J (Engl). 2015. PMID: 25591555 Free PMC article. Clinical Trial.
METHODS: Two-hundred and ten patients with hypertension and aged > 60 years were randomized to valsartan (n = 140) or amlodipine (n = 70) on admission. The primary endpoint was platelet aggregation rate (PAR) induced by arachidonic acid at discharge, and the seco …
METHODS: Two-hundred and ten patients with hypertension and aged > 60 years were randomized to valsartan (n = 140) or amlodipin …
Low Achieved Systolic Blood Pressure Related to Kidney Protection in Diabetic and Non-Diabetic High-Risk Hypertensive Patients.
Olsen E, Søraas CL, Schmieder RE, Jamerson K, MacDonald TM, Mancia G, Heimark S, Mehlum MH, Liestøl K, Larstorp ACK, Mariampillai JE, Mo R, Halvorsen LV, Høieggen A, Rostrup M, Kjeldsen SE, Weber MA. Olsen E, et al. Am J Hypertens. 2025 Nov 17;38(12):1106-1119. doi: 10.1093/ajh/hpaf093. Am J Hypertens. 2025. PMID: 40397037 Free PMC article. Clinical Trial.
METHODS: We analyzed patients 50-80 years with no cardiovascular events during the first 6 months of drug up-titration after randomization to valsartan or amlodipine, and with 3 or more visits onwards with standardized BP measurements. ...
METHODS: We analyzed patients 50-80 years with no cardiovascular events during the first 6 months of drug up-titration after randomization t …
Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial.
Calhoun DA, Lacourcière Y, Chiang YT, Glazer RD. Calhoun DA, et al. Hypertension. 2009 Jul;54(1):32-9. doi: 10.1161/HYPERTENSIONAHA.109.131300. Epub 2009 May 26. Hypertension. 2009. PMID: 19470877 Clinical Trial.
The efficacy/safety of the dual combinations of valsartan (Val)/hydrochlorothiazide (HCTZ) and amlodipine (Aml)/Val in hypertension are well established. ...
The efficacy/safety of the dual combinations of valsartan (Val)/hydrochlorothiazide (HCTZ) and amlodipine (Aml)/Val in hyperte …
206 results